Allgens(SH:688613) Zhi Tong Cai Jing·2026-02-27 08:11Core Viewpoint - Aojing Medical (688613.SH) reported a total operating revenue of 224 million yuan for the year 2025, representing a year-on-year growth of 8.48%, and achieved a net profit attributable to the parent company of 13.15 million yuan, marking a turnaround from loss to profit [1] Group 1: Financial Performance - The company achieved total operating revenue of 224 million yuan in 2025, reflecting an 8.48% increase compared to the previous year [1] - The net profit attributable to the parent company was 13.15 million yuan, indicating a successful turnaround from a loss [1] Group 2: Factors Influencing Performance - The growth in operating performance was primarily driven by the orthopedic artificial bone procurement, which provided opportunities for increased clinical usage and market share expansion [1] - The company strengthened its production assurance system to meet the increased demand resulting from the procurement [1] Group 3: Marketing Strategy - The company continued to deepen its regional market strategy through refined management and targeted marketing strategies, which helped to expand its sales network [1] - The overall operating revenue showed a steady growth trend, further consolidating the company's leading position in the niche market [1]